EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Localization and Tumor Growth Inhibition of I-131-Labeled Monoclonal Antibody ERIC1 in a Subcutaneous Xenograft Model of Small Cell Lung Cancer in SCID Mice

Thomas Fischer iD, Christopher Dietrich, Felix Dietlein iD, Sergio Muñoz Vázquez iD, Beate Zimmermanns iD, Philipp Krapf, Ferdinand Sudbrock, Alexander Drzezga, Markus Dietlein iD, Klaus Schomäcker

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms251910638 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Thomas Fischer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Xenograft Model Antitumor Assays, Lung Neoplasms, Mice, SCID. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluates the efficacy of [131I]I-ERIC1 in targeting and inhibiting the growth of SCLC tumors in mice, focusing on tumor accumulation and regression and potential side effects. NCAM-positive NCI-H69 SCLC cells were implanted in CB 17 SCID mice, and [131I]I-ERIC1 biokinetics were measured in organs and tissues at four post-injection time points (24, 72, 96, and 120 h). The experimental series compared tumor growth, survival, and changes in blood counts among three treatment groups (1, 2, or 3 MBq) and a control group, with treatments initiated either two or five days post implantation. [131I]I-ERIC1 was synthesized with >95% radiochemical purity and a specific activity of 15 TBq/mmol. Tumor activity peaked at 31.5 ± 6.6% ID/g after four days, demonstrating significant antitumor efficacy, which resulted in sustained remission and extended survival. Hematological toxicity was observed, with the optimal dose identified as 2 MBq per animal administered two days post implantation. [131I]I-ERIC1 shows promise as a theranostic agent for personalized cancer treatment by effectively targeting SCLC tumors with manageable side effects. However, further studies are required to optimize dosing strategies and minimize toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaXenograft Model Antitumor AssaysLung NeoplasmsMice, SCIDIodine RadioisotopesAnimalsMiceHumansCell Line, TumorAntibodies, MonoclonalFemaleTissue Distribution

Stichwörter der Autor:innen

ERIC1I-131SCLCanti-NCAM antibodybiokineticsmicenuclear medicinetheranosticstumor growth inhibition

Substanzen

Iodine RadioisotopesIodine-131Antibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
  • Institute and Polyclinic for Occupational Medicine, Environmental Medicine, and Preventive Research Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
  • Computational Health Informatics Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine (INM-5), Wilhelm-Johnen-Straße, 52428 Jülich, Germany.
  • German Center for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Venusberg-Campus 1/99, 53127 Bonn, Germany.

ORCID-Profile: Thomas Fischer, Felix Dietlein, Sergio Muñoz Vázquez, Beate Zimmermanns, Markus Dietlein

Zitieren

APA

Fischer, T., Dietrich, C., Dietlein, F., Muñoz Vázquez, S., Zimmermanns, B., Krapf, P., Sudbrock, F., Drzezga, A., Dietlein, M., & Schomäcker, K. (2024). Localization and Tumor Growth Inhibition of I-131-Labeled Monoclonal Antibody ERIC1 in a Subcutaneous Xenograft Model of Small Cell Lung Cancer in SCID Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910638

Vancouver

Fischer T, Dietrich C, Dietlein F, Muñoz Vázquez S, Zimmermanns B, Krapf P, et al. Localization and Tumor Growth Inhibition of I-131-Labeled Monoclonal Antibody ERIC1 in a Subcutaneous Xenograft Model of Small Cell Lung Cancer in SCID Mice. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910638

BibTeX
@article{Fischer2024,
  author = {Fischer, Thomas and Dietrich, Christopher and Dietlein, Felix and Muñoz Vázquez, Sergio and Zimmermanns, Beate and Krapf, Philipp and Sudbrock, Ferdinand and Drzezga, Alexander and Dietlein, Markus and Schomäcker, Klaus},
  title = {Localization and Tumor Growth Inhibition of I-131-Labeled Monoclonal Antibody ERIC1 in a Subcutaneous Xenograft Model of Small Cell Lung Cancer in SCID Mice},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms251910638}
}
Kostenlos starten →